ABBN.SW: $86.06 ▼ -0.04 (-0.05%)ASML.AS: $1,565.80 ▲ 5.00 (0.32%)ENR.DE: $160.10 ▼ -2.40 (-1.48%)GLEN.L: $535.70 ▲ 0.40 (0.07%)IFX.DE: $81.13 ▲ 0.57 (0.71%)NOKIA.HE: $12.20 ▲ 0.20 (1.67%)RIO.L: $7,278.00 ▲ 14.00 (0.19%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

BriaCell Therapeutics Corp.

BCTXW - NASDAQ

Identifiants & Marche

Ticker BCTXW
ISIN CA10778Y1126
CIK 0001610820
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays CA
Siege N/A
Fondee N/A
Site Web Lien

Description

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.